Lucid Diagnostics (NASDAQ:LUCD - Free Report) had its price objective boosted by Needham & Company LLC from $2.50 to $3.00 in a research note issued to investors on Monday morning,Benzinga reports. Needham & Company LLC currently has a buy rating on the stock.
Separately, Ascendiant Capital Markets decreased their price objective on Lucid Diagnostics from $7.25 to $7.00 and set a "buy" rating for the company in a research note on Monday, December 9th. Four equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus price target of $3.40.
Check Out Our Latest Analysis on LUCD
Lucid Diagnostics Stock Down 1.9 %
Shares of NASDAQ LUCD traded down $0.03 during midday trading on Monday, reaching $1.56. 613,348 shares of the company's stock traded hands, compared to its average volume of 364,779. The company has a market cap of $92.57 million, a price-to-earnings ratio of -1.37 and a beta of 1.34. Lucid Diagnostics has a one year low of $0.63 and a one year high of $1.63. The stock's 50 day simple moving average is $1.26 and its 200-day simple moving average is $1.00.
Institutional Trading of Lucid Diagnostics
A number of institutional investors have recently made changes to their positions in LUCD. LPL Financial LLC grew its position in Lucid Diagnostics by 29.1% during the 4th quarter. LPL Financial LLC now owns 53,391 shares of the company's stock worth $44,000 after purchasing an additional 12,035 shares during the last quarter. Sunbelt Securities Inc. acquired a new position in shares of Lucid Diagnostics in the 4th quarter valued at $67,000. Citadel Advisors LLC purchased a new position in Lucid Diagnostics in the 4th quarter worth $98,000. Lido Advisors LLC grew its stake in Lucid Diagnostics by 40.0% during the 4th quarter. Lido Advisors LLC now owns 140,016 shares of the company's stock valued at $115,000 after purchasing an additional 40,000 shares during the last quarter. Finally, Geode Capital Management LLC grew its stake in Lucid Diagnostics by 30.9% during the 4th quarter. Geode Capital Management LLC now owns 279,504 shares of the company's stock valued at $229,000 after purchasing an additional 65,964 shares during the last quarter. Institutional investors and hedge funds own 74.01% of the company's stock.
About Lucid Diagnostics
(
Get Free Report)
Lucid Diagnostics Inc operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma.
See Also
Before you consider Lucid Diagnostics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Lucid Diagnostics wasn't on the list.
While Lucid Diagnostics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
